· NY legislature · 2025-2026
Limits the substitution of abuse-deterrent analgesic opioid drug products for analgesic opioids lacking such technology
Provides for patient access to FDA approved abuse-deterrent technology to help combat opioid abuse.
- Sponsor
- Andrew Lanza (R-NY)
- Introduced
- 2025-03-27
- Latest action
- REFERRED TO INSURANCE
Digging through Congress... 🔍